新華聯(000620.SZ):終止2015年非公開發行股票事項
格隆匯 6 月 17日丨新華聯(000620.SZ)公佈,2016年12月22日,西南證券向中國證監會提交了《關於新華聯文化旅遊發展股份有限公司2015年非公開發行股票之複核報告》,擬向中國證監會申請換髮非公開發行股票批覆,但受政策影響至今未有進展。
由於資本市場行情變化等原因,公司決定不再提請董事會和股東大會審議延長非公開發行股票股東大會決議有效期、提請股東大會延長授權董事會辦理非公開發行股票相關事宜有效期等議案,此次非公開發行股票事項已超過股東大會決議有效期而自動終止,且公司已於近日收到《中國證監會行政許可申請終止審查通知書》,終止公司非公開發行股票申請的審查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.